News

Tysabri Treatment Leads to Disease Activity-free Status in Patients with Pediatric-onset MS

Early treatment with Tysabri (natalizumab) of patients with aggressive pediatric-onset multiple sclerosis is highly effective at achieving disease activity-free status and preventing cognitive decline, a new study shows. The study, “No evidence of disease activity including cognition (NEDA-3 plus) in naïve pediatric multiple sclerosis patients treated with natalizumab,”…

RRMS Patients Not Using DMTs More Likely to Have Been Misdiagnosed, Cite Poorer Relationships with Doctors, Survey Says

People with relapsing-remitting multiple sclerosis (RRMS) who don’t use disease-modifying therapies (DMTs) are more likely to have been misdiagnosed previously, and to have poorer relationships with their healthcare providers, the results of a new survey suggest. The survey, titled “Multiple Sclerosis In America 2019,” was conducted by …

Tests of Cognitive Abilities Very Useful in Judging Everyday Life Skills, But Study Advises Pairing with Other Tests

Testing cognitive abilities — like learning and memory, processing speed, and verbal fluency — can give valuable clues as to how well people with multiple sclerosis (MS) are able to go about their daily lives, according to a review study led by Kessler Foundation researchers. Neuropsychological tests are of “significant predictive…

#ECTRIMS2019 – Is Rituximab a Reasonable Option for MS Patients?

Editor’s note: This is the first story in a three-part report examining the question, “Is rituximab a reasonable alternative treatment for MS?”, which was a topic discussed at this year’s Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Here, we provide a synopsis of…

Profiling Inflammatory Markers in Cerebrospinal Fluid of Importance in Active MS, Case Study Finds

Careful profiling of inflammatory markers in cerebrospinal fluid (CSF) of multiple sclerosis patients, coupled with standard exams and scans, helps in understanding disease evolution and treatment response, a case report suggests. It followed a relapsing-remitting multiple sclerosis (RRMS) patient whose inflammatory markers in the CSF remained high over time, and…